Genomic Health (GHDX) Reports Multiple Studies Reinforcing Value of Oncotype DX Tests in Guiding Treatment for Breast & Prostate Cancer Patients
Genomic Health, Inc. (NASDAQ: GHDX) today announced results from multiple studies of its Oncotype DX® tests highlighting their value in ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)